Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Merck (NYSE: MRK) announced positive Phase 3 CORALreef Lipids trial results for enlicitide, an investigational once-daily oral PCSK9 inhibitor, demonstrating a statistically significant and clinically meaningful 55.8% reduction in LDL-C at week 24, sustained at 47.6% at one year, with a safety profile comparable to placebo. If approved, this potential first-in-class oral PCSK9 inhibitor could address significant unmet needs in atherosclerotic cardiovascular disease (ASCVD) by offering a convenient and effective treatment option for patients not achieving LDL-C goals with existing therapies, representing a substantial market opportunity.

Analysis

Merck (NYSE: MRK) has announced highly positive Phase 3 CORALreef Lipids trial results for enlicitide, an investigational once-daily oral PCSK9 inhibitor. The drug demonstrated a statistically significant and clinically meaningful 55.8% reduction in low-density lipoprotein cholesterol (LDL-C) at week 24, with sustained reductions of 47.6% at one year. Crucially, enlicitide exhibited a safety profile comparable to placebo, addressing a key concern for long-term cardiovascular treatments.

These compelling results position enlicitide as a potential first-in-class oral PCSK9 inhibitor, offering a significant convenience advantage over existing injectable PCSK9 therapies. This oral formulation could substantially improve patient adherence and address the unmet needs of millions of atherosclerotic cardiovascular disease (ASCVD) patients who currently do not achieve target LDL-C levels with statins or injectables, representing a substantial market opportunity.

Beyond LDL-C, enlicitide also showed significant reductions in other atherogenic lipids like non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and lipoprotein(a) (Lp(a)), further strengthening its therapeutic profile. Merck plans to submit these data, along with results from other CORALreef trials, to regulatory authorities worldwide. Successful approval would solidify Merck's position in the high-growth cardiovascular market, leveraging its novel macrocyclic peptide platform.

Key Decisions for Investors

• Investors should consider the strong clinical data and potential first-mover advantage of an oral PCSK9 inhibitor as a significant long-term growth driver for Merck.
• Monitor regulatory approval timelines and commercial launch strategies closely, as market penetration will depend on physician adoption and payer coverage.
• Evaluate the competitive landscape, particularly how enlicitide's oral convenience will impact the market share of existing injectable PCSK9 inhibitors and other lipid-lowering therapies.